Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 4,182.00
+2.00 (0.05%)
At close: Nov 10, 2025
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
93.08M JPY
Profits / Employee
696.98K JPY
Market Cap
6.61T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| Daiichi Sankyo Company | 19,765 |
| M3, Inc. | 15,360 |
| Astellas Pharma | 13,643 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Takeda Pharmaceutical Company News
- 2 days ago - Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy - Nasdaq
- 3 days ago - Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy - Business Wire
- 7 days ago - New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization - Business Wire
- 10 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 11 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 11 days ago - Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha